We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-11.00 | -0.67% | 1,629.00 | 1,629.00 | 1,629.50 | 1,641.00 | 1,611.00 | 1,633.00 | 6,977,520 | 16:29:59 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.61 | 67.07B |
Date | Subject | Author | Discuss |
---|---|---|---|
06/8/2020 19:16 | It's worse elsewhere as I'm sure you must have seen.. this place is an oasis of positivity and calm compared to some! | rikky72 | |
06/8/2020 18:15 | Feelin the luv on this board.... | geckotheglorious | |
06/8/2020 11:38 | ...and by the way, of course the price will drop on ex div day you total plonker. | porsche1945 | |
06/8/2020 11:16 | @aibizle Depends what you want, a share that has zero growth, large debt, a patent cliff and a possibly soon to be cut dividend, and soso unexceptional U.K. style management OR growth? Buying shares for dividends is a mugs game, the ftse 350 full of dross, buy high quality US tech trusts and make real money rather than chasing a poxy 5 pc a year. If you want to buy U.K. pharma for some reason, buy Astra, amazing drug pipeline, the big money in cancer drugs, not sensodyne toothpaste. Gsk for trading purposes only and I love it for that, as an investment, pointless. | porsche1945 | |
06/8/2020 06:40 | Yes, its worth buying now - the price is disproportionately low and the prospects are exceedingly high. Ignore the dividend 'effect'. The price always quickly recovers after an (not always) initial fall. Today's FDA approval is the fifth major medicine approval for GSK in 2020. | tradermichael | |
06/8/2020 00:26 | Is it worth buying now or will price drop on ex dividend day | alibizzle | |
05/8/2020 15:30 | Althugh don't trust graphs....does the one above seem to show the share price in a long slow decline since second week of May/ Any logical reason? | bothdavis | |
05/8/2020 11:54 | I know everyone values a stock differently, but I like analyst site Simply Wall Street they have fair value price of 2555p. Now that would be nice boys. | montyhedge | |
05/8/2020 11:35 | Under 1600p gift from the stockmarket gods, ex div 13th August, 19p in the bag. | montyhedge | |
05/8/2020 10:58 | Just love it when that guy with the old Porsche gets it wrong again. Been some great buy-in opportunities recently. | montedawnster | |
05/8/2020 09:15 | Emma W should have used this in her results presentation! Thanks TM. | jadeticl3 | |
05/8/2020 08:31 | Good post. | montyhedge | |
05/8/2020 08:26 | TM Well reasoned post. Thanks. | redartbmud | |
05/8/2020 07:58 | GSK is currently trading with a P/E ratio of 13.67 right now. For comparison, its industry sports an average P/E of 15.07. Over the past year, GSK's Forward P/E has been as high as 15.37 and as low as 10.51, with a median of 14.16. Another valuation metric is GSK's P/B ratio of 3.93. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 6.69. Over the past 12 months, GSK's P/B has been as high as 27.58 and as low as 3.39, with a median of 4.72. Also note the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. This is a preferred metric because revenue can't really be manipulated, so sales are often a truer performance indicator. GSK has a P/S ratio of 2.35. This compares to its industry's average P/S of 4.33. Finally, recognize that GSK has a P/CF ratio of 13.10. This metric takes into account a company's operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 15.31. GSK's P/CF has been as high as 13.63 and as low as 8.88, with a median of 11.78, all within the past year. The above data help show that GlaxoSmithKline is likely undervalued currently. And when considering the strength of its earnings outlook, GSK sticks out at as one of the market's strongest value stocks. | tradermichael | |
04/8/2020 14:23 | Can only be sentiment over a superior pipeline of potential products. If GSK were gifted a similar p/e as AZN, what would the GSK price be? | tradermichael | |
04/8/2020 14:18 | How do we get to the ridiculously high p/e numbers of azn? | barony | |
04/8/2020 11:43 | 13th August ex div date. At least 19p in the bag, while waiting for higher shareprice. | montyhedge | |
04/8/2020 10:37 | Strong bull, until 2050p. If they are first with a vaccine. | montyhedge | |
04/8/2020 09:01 | He's here, he's there, a strong bull, then a complete bear.. | rikky72 | |
04/8/2020 08:58 | jadeticl3 no - I did not - but this one looks remarkably similar to the one who posted "19p, down 100p. Dividend boys caught a cold" (post 21307) around the time of the last results.... | robbiekeane | |
04/8/2020 07:23 | Robbie Keane, did you not know there are three Monties? | jadeticl3 | |
03/8/2020 16:32 | I recall Monty didn't hold for the dividend last quarter.... | robbiekeane | |
03/8/2020 16:13 | If GSK/Sanofi first with vaccine these will touch 2000p in my view. | montyhedge | |
03/8/2020 16:11 | Toffeeman Dividend paid every 13 weeks, of course not 5% per quarter, lol. | montyhedge |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions